Loading stock data…
OKYO Pharma Limited (OKYO)
$1.50-0.02 (-1.32%)
After Hours$1.50+0.00 (+0.00%)· Last close Jun 30
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
OKYO Pharma Limited in the Healthcare sector is trading at $1.50 with a market capitalization of $87M. Wall Street consensus targets $9.00 (3 analysts), implying a +500.0% move over the next 12 months. The stock is currently near its 52-week low of $1.42, remaining 21.9% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +500.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q3 2025 | Q1 2025 | Q3 2024 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | — | — | — | — | — |
Peer Comparison
JNJUNHPFE
Fundamentals
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$87.12M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.05
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-
Volume
Today's trading volume
112,472
Recent News
OKYO Pharma expands scientific advisory board with cornea expert - ICYMI
OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week announced the appointment of Dr. Marta Sacchetti to its scientific advisory board as the company advances development of its lead ophthalmic candidate targeting neuropathic corneal pain. Speaking with Proactive, CEO Robert Dempsey said...
What Makes OKYO Pharma (OKYO) a New Buy Stock
OKYO Pharma (OKYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
OKYO Pharma Strengthens Scientific Advisory Board With Marta Sacchetti Appointment
OKYO Pharma’s CEO Robert Dempsey joined Steve Darling from Proactive to announce the appointment of Dr. Marta Sacchetti, MD, PhD, as the newest member of the company’s Scientific Advisory Board (SAB), a move designed to further strengthen the company’s scientific and clinical expertise as it advances its lead ophthalmic programs. Dempsey explained that Sacchetti’s addition enhances OKYO Pharma’s already distinguished global network of scientific and medical advisors. Widely recognized for her expertise in neuro-inflammatory corneal diseases, Sacchetti brings deep knowledge and extensive research experience that aligns with the company’s mission to address significant unmet needs in ophthalmology and ocular surface disease treatment. Sacchetti currently serves as an Associate Professor of Ophthalmology at Link University in Rome, Italy, and has built a strong reputation through her work spanning clinical practice, research, and industry collaboration. Her previous experience as Global Head of Clinical Development, Ophthalmology & Neurotrophins at Dompé Farmaceutici adds another important dimension to her expertise, particularly in areas involving targeted nerve regeneration, pain signaling modulation, and advanced diagnostic approaches. Her research efforts have focused heavily on degenerative, allergic, and neuroimmune diseases affecting the cornea and ocular surface. In addition to her clinical contributions, Sacchetti has authored numerous peer-reviewed scientific publications and presented her findings at leading national and international conferences, reinforcing her standing within the global ophthalmology community. Dempsey noted that her appointment comes at an important stage for OKYO Pharma as the company advances its investigational treatment pipeline. The company’s lead product candidate, Urcosimod, continues to gain attention as the first investigational therapy to receive an Investigational New Drug (IND) designation specifically for the treatment of neuropathic corneal pain. The program has also been granted Fast Track designation by the U.S. Food and Drug Administration, potentially accelerating its path through development and regulatory review. The appointment reflects OKYO Pharma’s ongoing strategy of adding specialized expertise to support the development and commercialization of novel therapies aimed at addressing challenging ophthalmic conditions. #proactiveinvestors #okyopharmalimited #nasdaq #okyo #Urcosimod #NeuropathicCornealPain #HealthcareInnovation #ClinicalDevelopment #NeuroInflammation #CornealDisease #Pharmaceuticals #MedTech #DrugDevelopment #MartaSacchetti
OKYO Pharma adds ophthalmology specialist Marta Sacchetti to Scientific Advisory Board
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has expanded its Scientific Advisory Board with the appointment of Dr. Marta Sacchetti as the company continues advancing its clinical programs in neuropathic corneal pain and inflammatory eye diseases. The clinical-stage biopharmaceutical...
OKYO Pharma to hold Scientific Advisory Board meeting at ASCRS 2026
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company focused on treatments for neuropathic corneal pain (NCP) and inflammatory eye diseases, has announced plans to convene a Scientific Advisory Board (SAB) meeting during the 2026 American Society of Cataract and Refractive...